<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101208441</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32337</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Alzheimer Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Alzheimer Res</journal-id>
<journal-title-group>
<journal-title>Current Alzheimer research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1567-2050</issn>
<issn pub-type="epub">1875-5828</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27697064</article-id>
<article-id pub-id-type="pmc">5328927</article-id>
<article-id pub-id-type="doi">10.2174/1567205013666160930110551</article-id>
<article-id pub-id-type="manuscript">NIHMS841292</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Decourt</surname>
<given-names>Boris</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lahiri</surname>
<given-names>Debomoy K.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sabbagh</surname>
<given-names>Marwan N.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>School of Life Sciences, Arizona State University, Tempe, AZ, USA</aff>
<aff id="A2"><label>2</label>Banner Sun Health Research Institute, Sun City, AZ, USA</aff>
<aff id="A3"><label>3</label>Institute of Psychiatry Research, Department of Psychiatry, School of Medicine, Indiana University-Purdue University, Indianapolis, IN, USA</aff>
<aff id="A4"><label>4</label>Department of Medical and Molecular Genetics, School of Medicine, Indiana University-Purdue University, Indianapolis, IN, USA</aff>
<aff id="A5"><label>5</label>Barrow Neurological Institute, Phoenix, AZ, USA</aff>
<author-notes>
<corresp id="cor1"><label>*</label>Address correspondence to these authors at the Banner Sun Health Research Institute, 10515 W. Santa Fe Dr., Sun City AZ 85351, USA; Tel: +1 623-832-2973; <email>Boris.Decourt@bannerhealth.com</email>; and Director, Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute, 240 West Thomas, Ste 301, Phoenix, AZ 85013, USA; Tel: +1-602-406-4784; <email>Marwan.Sabbagh@DignityHealth.org</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P49">
<bold>CONFLICT OF INTEREST</bold>
</p>
<p id="P50">The author(s) confirm that this article content has no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>14</volume>
<issue>4</issue>
<fpage>412</fpage>
<lpage>425</lpage>
<!--elocation-id from pubmed: 10.2174/1567205013666160930110551-->
<abstract>
<p id="P1">Alzheimer’s disease (AD) affects an estimated 44 million individuals worldwide, yet no therapeutic intervention is available to stop the progression of the dementia. Neuropathological hallmarks of AD are extracellular deposits of amyloid beta (Aβ) peptides into plaques, intraneuronal accumulation of hyperphosphorylated tau protein forming tangles, and chronic inflammation. A pivotal molecule in inflammation is the pro-inflammatory cytokine TNF-α. Several lines of evidence using genetic and pharmacological manipulations indicate that TNF-α signaling exacerbates both Aβ and tau pathologies <italic>in vivo</italic>. Interestingly, preventive and intervention anti-inflammatory strategies demonstrated a reduction in brain pathology and an amelioration of cognitive function in rodent models of AD. Phase I and IIa clinical trials suggest that TNF-α inhibitors might slow down cognitive decline and improve daily activities in AD patients. In the present review, we summarize the evidence pointing towards a beneficial role of anti-TNF-α therapies to prevent or slow the progression of AD. We also present possible physical and pharmacological interventions to modulate TNF-α signaling in AD subjects along with their limitations.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer’s disease</kwd>
<kwd>BACE1</kwd>
<kwd>Etanercept</kwd>
<kwd>Inflammation</kwd>
<kwd>Neuroinflammation</kwd>
<kwd>thalidomide</kwd>
<kwd>TNF-α</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>